Physician profile
Jigna Thakore
NPI 1750488946
$15,362.36
in general payments reported to CMS, 2019-2025
46 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,630 · 2020: $984 · 2021: $1,843 · 2022: $2,600 · 2023: $2,507 · 2024: $2,886 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,209 · Education: $96.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,208.94 |
| Education | $96.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,583.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,896.43 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,440.10 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,298.38 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $836.26 | 2019-2025 | |
| Celgene Corporation | $616.85 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $606.85 | 2021-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $556.46 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $426.01 | 2024-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $277.70 | 2019-2023 | Ocaliva |
| Lilly USA, LLC | $270.28 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $221.37 | 2022 | |
| Ardelyx, INC. | $199.07 | 2022-2025 | Ibsrela |
| Braintree Laboratories, INC. | $189.12 | 2021-2025 | Sutab, Suflave |
| Daiichi Sankyo INC. | $171.25 | 2019-2024 | Injectafer |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigna Thakore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.